NVIDIA's cloud gaming service expands with 15 new titles this month, headlined by Pearl Abyss' Crimson Desert launching March 19 with RTX 5080 support. (Read MoreNVIDIA's cloud gaming service expands with 15 new titles this month, headlined by Pearl Abyss' Crimson Desert launching March 19 with RTX 5080 support. (Read More

NVIDIA GeForce NOW Adds 15 Games in March Including Crimson Desert

2026/03/05 22:51
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

NVIDIA GeForce NOW Adds 15 Games in March Including Crimson Desert

Jessie A Ellis Mar 05, 2026 14:51

NVIDIA's cloud gaming service expands with 15 new titles this month, headlined by Pearl Abyss' Crimson Desert launching March 19 with RTX 5080 support.

NVIDIA GeForce NOW Adds 15 Games in March Including Crimson Desert

NVIDIA's cloud gaming platform is loading up for March with 15 new titles joining the GeForce NOW library, including several day-one releases optimized for the company's latest RTX 5080 hardware.

The headline addition is Pearl Abyss' Crimson Desert, an open-world action-adventure dropping March 19. The game joins a lineup that kicked off this week with eight titles, including Kingdom Come: Deliverance II (available on Game Pass) and the highly anticipated Slay the Spire 2.

Four games in the March batch arrive with RTX 5080 optimization out of the gate: Kingdom Come: Deliverance II, The Legend of Khiimori, Death Stranding Director's Cut, and John Carpenter's Toxic Commando (March 12). That's notable for cloud gaming subscribers who get access to NVIDIA's top-tier hardware without owning it.

The Full March Lineup

This week's additions include Legacy of Kain: Defiance Remastered, Esoteric Ebb, and LORT—the latter described by developer Big Distraction as an "off-the-rails adventure" built around chaotic gameplay moments.

The rest of March looks solid: Everwind arrives March 17, Screamer on March 23, Nova Roma hits March 26 with Game Pass availability, and the month closes out with Legacy of Kain: Ascendance and Subliminal on March 31.

NVIDIA also quietly added 18 games in February beyond its announced 24, bringing titles like Diablo II: Resurrected, Mega Man 11, and the Street Fighter 30th Anniversary Collection to the cloud service.

Platform Context

GeForce NOW has been running since its 2020 public launch, operating on a freemium model where free users get one-hour sessions while paid Ultimate subscribers access priority queues and extended playtime. The service lets players stream their existing Steam, Epic, and Ubisoft libraries from NVIDIA's servers—useful for anyone gaming on hardware that can't handle modern titles natively.

NVIDIA stock closed at $183.18 on March 4, up 1.75% on the day, with the company's market cap sitting at $4.45 trillion. The gaming segment remains a smaller piece of NVIDIA's business compared to AI and data center operations, but consistent GeForce NOW updates keep the platform competitive against Xbox Cloud Gaming and PlayStation's streaming offerings.

Crimson Desert's March 19 launch will likely be the month's biggest test for the service's infrastructure. Pearl Abyss built the game on its proprietary engine, and day-one cloud availability could drive significant subscriber activity.

Image source: Shutterstock
  • nvidia
  • geforce now
  • cloud gaming
  • crimson desert
  • gaming
Market Opportunity
Cloud Logo
Cloud Price(CLOUD)
$0.03724
$0.03724$0.03724
+0.56%
USD
Cloud (CLOUD) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09